Market Overview - The Hang Seng Index is expected to be constrained by this year's high of 28,056 points due to the hawkish stance of the newly appointed Federal Reserve Chairman and a rebound in the US dollar index, which has led to profit-taking in the commodity market [2] - The Chinese government is anticipated to focus on expanding domestic demand and technological self-sufficiency in the first quarter of 2026, as it marks the beginning of the 15th Five-Year Plan [2] - There is a policy vacuum in China ahead of the Two Sessions, with many provinces lowering their GDP growth targets, leading to expectations of a GDP growth target of 4.5%-5% for 2026, down from approximately 5% in 2025 [2] Company News - Alphabet is expected to raise $32 billion through a rare issuance of century bonds in GBP [4] - Alibaba has launched the RynnBrain model, which aims to give robots a "thinking brain" [4] - Semiconductor manufacturer SMIC reported a 61% increase in profits last quarter, exceeding revenue guidance [4] - WuXi Biologics has issued a profit warning, expecting a 46% increase in profits for the previous year [4] Economic Outlook - The Federal Reserve maintained interest rates in January, aligning with market expectations, and expressed a positive outlook on economic activity, indicating a cautious approach to future rate adjustments based on economic data [4] - Recent economic data has shown resilience, which may limit the scope for interest rate cuts in the near term [4] - Geopolitical tensions have led to a rebound in oil prices, although an oversupply situation is expected to limit the upward movement of international oil prices [4] Sector Focus - The travel sector is experiencing strong demand as the Lunar New Year approaches [7] - The AI sector is seeing rapid growth due to intensive upgrades in AI models, benefiting the semiconductor industry [7] - The innovative pharmaceutical sector continues to see significant licensing deals and ongoing international expansion [7] Macro Focus - The People's Bank of China is expected to implement a moderately loose monetary policy, utilizing tools such as reserve requirement ratio cuts and interest rate reductions to support economic growth and stabilize prices [8] - The central bank aims to maintain liquidity and financing conditions that align with economic growth and price level expectations [8]

Core Viewpoint - The Shanghai 180 ETF Index Fund closely tracks the Shanghai 180 Index, which reflects the overall performance of 180 large-cap and liquid securities in the Shanghai stock market, showing a recent upward trend in both the index and the fund itself [1][2]. Performance Summary - As of February 10, 2026, the Shanghai 180 Index increased by 0.26%, with notable gains from stocks such as China Power (+9.99%) and Dongfang Electric (+8.34%) [1]. - The Shanghai 180 ETF Index Fund rose by 0.24%, with a latest price of 1.26 yuan, and has accumulated a 1.37% increase over the past week [1]. - The fund's trading volume was 23.03 thousand yuan on February 10, with an average daily trading volume of 65.87 thousand yuan over the past week [1]. Fund Size and Growth - The Shanghai 180 ETF Index Fund experienced a significant growth of 622.11 thousand yuan in size over the past year [1]. - The fund has a Sharpe ratio of 1.91 since its inception, indicating a favorable risk-adjusted return [1]. Fee Structure - The management fee for the Shanghai 180 ETF Index Fund is set at 0.15%, while the custody fee is 0.05% [1]. Tracking Accuracy - As of February 10, 2026, the tracking error of the Shanghai 180 ETF Index Fund over the past three months is 0.019%, demonstrating its effectiveness in tracking the underlying index [1]. Top Holdings - As of January 30, 2026, the top ten weighted stocks in the Shanghai 180 Index account for 24.85% of the index, including major companies like Zijin Mining and Kweichow Moutai [2]. - The top ten stocks by weight are: - Zijin Mining (4.03%) - Kweichow Moutai (4.22%) - China Ping An (2.87%) - Hengrui Medicine (2.46%) - WuXi AppTec (2.08%) - Cambricon (1.97%) - China Merchants Bank (2.04%) - Yangtze Power (1.88%) - SMIC (1.80%) - Industrial Fulian (1.79%) [3].

Market Trends - The domestic market indices showed slight fluctuations, with the Shanghai Composite Index closing at 4,128.37, up by 0.13% [4] - During the period from February 2 to February 8, major indices experienced declines, with the Shanghai Composite Index down by 1.27% and the ChiNext Index down by 3.28% [7] Industry Insights - The non-bank financial sector is seeing a revision in underwriting regulatory guidelines, which is expected to enhance investment value in the sector [5] - The media industry is projected to continue its upward trend, driven by AI applications and IP ecosystems, with a 27.17% increase in the media index for 2025 [6] - The power equipment and new energy sector is focusing on the AIDC power revolution, with expectations for a significant increase in photovoltaic power utilization rates [8][19] - The agricultural sector is facing potential price adjustments in pig farming after a peak season, with current prices showing a downward trend [15][17] Company Analysis - Aide Technology is recognized as a leader in domestic spinal vertebral body shaping systems, benefiting from an aging population [22] - Tianfu Communication's 2025 performance forecast indicates a net profit of 1.88 to 2.15 billion yuan, driven by stable demand for optical devices [26] - Wolong Nuclear Materials anticipates a net profit of 1.1 to 1.18 billion yuan for 2025, with strong market demand across various business segments [28] Investment Recommendations - The report suggests focusing on companies that leverage AI applications and IP development, such as Kunlun Wanwei and Shanghai Film [9] - In the photovoltaic sector, companies like Aishuo and Longji Green Energy are recommended due to their technological advancements and market positioning [16][23] - For the copper connection market, companies like Wolong Nuclear Materials are highlighted for their strong growth potential in the telecommunications sector [28]

Key Points - Infineon expects the gallium nitride market to achieve a compound annual growth rate of 44% from 2025 to 2030 [1] - Huahong Semiconductor has received approval from the Shanghai State-owned Assets Supervision and Administration Commission for its asset purchase and fundraising plan [1] - Yunnan Energy Holdings is planning to acquire a stake in Xiantian Computing Technology Co., Ltd. and is in the process of acquiring controlling interest in Zhengzhou Heying Data Co., Ltd. [1] - Heng Rui Medicine's subsidiary has had a new indication for its injectable drug accepted by the National Medical Products Administration [1] - Fosun Pharma's subsidiary has had its drug registration application accepted by the National Medical Products Administration [1] Investment, Contracts, and Bids - Zhongtung High-tech plans to invest 145 million yuan in a new project to produce 30 million PCB drill needles annually [1] - China Railway Construction recently won major contracts totaling 45.142 billion yuan [1] - Tianneng Wind Power has signed new offshore engineering contracts worth 870 million yuan [1] - Yunjigroup's wholly-owned subsidiary has signed an EPC general contracting agreement worth 1.331 billion yuan, accounting for 86.66% of the company's audited revenue for 2024 [1] Performance - SMIC reported a net profit of 1.223 billion yuan for Q4 2025, representing a year-on-year increase of 23.2% [1] - Huichuan Technology expects a year-on-year increase in net profit of 16%-26% for 2025, with significant growth in its electric vehicle business [1]

Group 1: Market Overview - The overall market shows a mixed performance with the Shanghai Composite Index closing at 4128.37, up by 0.13%, while the ChiNext Index fell by 0.37% to 3320.54 [8][9] - The AI application sector is leading the market, particularly with the launch of ByteDance's Seedance 2.0, which enhances video generation capabilities [8][10] - The trading volume decreased, with a total market turnover of 21,247.45 billion, down by 1,454.35 billion from the previous trading day [9] Group 2: Industry Dynamics - ByteDance's Seedance 2.0 has been launched, enabling the creation of high-quality videos from text or images, which is expected to revolutionize the film industry [27][28] - The 2025 Hunan electricity market settlement report indicates a retail settlement average price of 0.45 yuan per kilowatt-hour, with significant transaction volumes reported [29][30] Group 3: Company Updates - Semiconductor company SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, with total revenue reaching 178.13 billion, a growth of 11.9% [31][32] - Heng Rui Medicine's application for the marketing license of its drug has been accepted and prioritized for review, targeting HER2-positive colorectal cancer [34] - Huami New Materials reported stable growth with a revenue increase of 6.44% and a net profit increase of 10.86% for 2025 [35][36] Group 4: Economic Initiatives - Hunan Province has initiated ten key livelihood projects for 2026, with a total investment of 601 billion, reflecting a 5.2% increase from 2025 [38][39]

顾忠泽介绍，器官芯片技术是在微流控芯片上构建一个微型仿生系统，如同为细胞搭建一个"智慧房 屋"。微流控是在微米尺度的通道中精确控制微量流体的技术。因此，这样的"智慧房屋"能提供营养， 更能精密控制微环境，实时监测在其中生长的类器官的"生命体征"。 科研人员利用微型仿生系统，能在人体外高效、精准地模拟人体器官对药物或外界刺激的反应。团队发 现，在检测药物肝毒性方面，器官芯片达到90%及以上准确率，而传统动物实验的准确率通常在50%— 60%。 □ 本报记者 谢诗涵 徐冠英 近日，美国环境保护署（EPA）宣布，加速实现"到2035年终止所有由EPA开展或资助的哺乳动物实 验"的政策目标，推动毒理学评估从依赖动物模型转向基于人类细胞、器官芯片、人工智能和高通量体 外测试的新方法学。 随着"非动物实验浪潮"来袭，器官芯片技术日益受到关注。目前，国内器官芯片领域的研究团队尚属少 数。其中，东南大学器官芯片研究院院长、数字医学工程全国重点实验室主任顾忠泽团队"十年磨一 剑"，成功推动成果产业化，是该领域极具代表性的团队。近日，记者走进这支团队及其孵化的江苏艾 玮得生物科技有限公司，探秘器官芯片究竟如何运作、有什么作用、已 ...

Core Insights - Major multinational pharmaceutical companies are showing robust revenue growth and increased sales of core products as they release their 2025 performance results [1][2] - Johnson & Johnson leads with nearly $94.2 billion in revenue, while Eli Lilly's weight loss drug, tirzepatide, shows a remarkable 45% year-over-year growth [1][2] Group 1: Revenue Performance - Johnson & Johnson reported total revenue of $94.193 billion for 2025, marking a 6% increase year-over-year [2] - Roche follows with revenue of $74.428 billion, while Eli Lilly, Merck, Pfizer, and AbbVie each exceeded $60 billion in revenue [2] - Eli Lilly's revenue reached $65.179 billion, a 44.7% increase, driven by strong sales of tirzepatide, which generated $36.5 billion [6] Group 2: Product Performance - Johnson & Johnson's innovative pharmaceuticals and medical technology segments both achieved revenue growth, with $60.401 billion and $33.792 billion respectively, both up by approximately 6% [2] - The CAR-T therapy, ciltacabtagene autoleucel, contributed significantly to Johnson & Johnson's growth, with revenue of $1.887 billion, a 95.9% increase [2] - Eli Lilly's tirzepatide sales reached $36.5 billion, with the weight loss version generating $13.542 billion, a 175% increase [6] Group 3: Market Trends and Challenges - The pharmaceutical industry faces a looming "patent cliff," with an estimated $236 billion in revenue at risk from patent expirations between 2025 and 2030 [8] - Companies are increasingly engaging in business development transactions to replenish their R&D pipelines, with Chinese innovative pharmaceutical companies gaining prominence [8][9] - In 2025, Chinese companies achieved record-breaking business development deals, totaling $135.655 billion, with significant collaborations involving major multinational firms [9]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly marks their seventh partnership, focusing on the development of innovative drugs in oncology and immunology, with significant financial implications for Innovent [2][5]. Financial Aspects - Innovent will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [2]. - The company’s stock price rose by 7.42% to HKD 85.4 per share, with a market capitalization nearing HKD 150 billion as of February 9 [3]. Historical Context - The partnership dates back to 2015, yielding successful products such as the PD-1 antibody, Sintilimab, and the GLP-1 receptor agonist, MaShidu [4]. - Sintilimab has been a cornerstone of Innovent's commercialization strategy, rapidly entering the domestic market and becoming a key product in their portfolio [4]. Strategic Development - The collaboration emphasizes a new model of business development, focusing on entirely new targets and molecules rather than existing products [2][5]. - Innovent will lead the projects from drug discovery to clinical validation in China, while Eli Lilly retains global rights outside of Greater China [5]. Industry Trends - The partnership reflects a broader trend where multinational pharmaceutical companies are increasingly interested in early-stage innovative assets from Chinese firms, moving away from established clinical pipelines [6]. - This shift is seen as a necessary evolution in the research paradigm, allowing for systematic validation of technologies across multiple targets while managing costs [6]. Future Outlook - Innovent's product revenue is projected to reach approximately CNY 11.9 billion in 2025, marking a 45% year-on-year increase, with significant contributions from its oncology and chronic disease product lines [8]. - The company has three core assets expected to enter or are already in international Phase III clinical trials, with a combined market potential exceeding $60 billion [8][9]. Product Pipeline - The new generation IO therapy, IBI363, is anticipated to have a market potential exceeding $40 billion, while IBI343 and IBI324 are also expected to contribute significantly to revenue, with market potentials of over $8 billion and $15 billion, respectively [9][10].

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report highlights significant advancements in the pharmaceutical industry, particularly in the development and approval of innovative drugs, with a focus on oncology and immunotherapy [5][6][10]. Summary by Sections 1. Latest Policy Updates - The National Medical Products Administration (NMPA) has issued several key announcements, including guidelines to strengthen the supervision of entrusted drug production and the release of the 2025 Clinical Application Guidelines for Antitumor Drugs [10][15][18]. - New regulations aim to support the development of innovative drugs and ensure the quality and safety of pharmaceuticals through enhanced management practices [11][12][14]. 2. Domestic New Drug Approvals - In January 2026, a total of 172 new drugs were approved for clinical trials, a decrease of 55 from the previous month. Among these, 78 were chemical drugs, 88 were biological products, and 6 were traditional Chinese medicines [22][23]. - The majority of new drug approvals were in the fields of oncology and immune modulation, accounting for 53% of the total [22]. 3. Global Innovative Drug Development - The report lists several drugs that have shown positive clinical results, including Neumora Therapeutics' NMRA-511 and GSK's new hepatitis B drug, which achieved success in phase 3 studies [6][10]. - Notable approvals include the BCL-2 inhibitor from BeiGene, which received dual indications for chronic lymphocytic leukemia and mantle cell lymphoma [40][41]. 4. New Drug Listings - The report details new drug listings, including the approval of the combination drug for ADHD treatment by Aikobai, which has shown significant efficacy in clinical trials [41][43]. - The approval of Merck's drug for pulmonary arterial hypertension represents a new treatment option that addresses the underlying causes of the disease rather than just symptomatic relief [40].

Investment Rating - The report does not explicitly provide an investment rating for Innovent Biologics [4]. Core Insights - Innovent Biologics announced a milestone deal with Eli Lilly on February 8, 2026, granting overseas rights to certain oncology and immunology pipeline assets, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [4][5]. - This transaction is viewed positively, reinforcing the recognition of Innovent's R&D capabilities by global pharmaceutical companies, which is a significant differentiator in the Chinese biotech sector [6]. - The company is expected to release at least nine Phase I/II data assets in oncology, cardiovascular/metabolic diseases, and autoimmune diseases between 2026 and early 2027, which could unlock substantial option value [6]. Summary by Sections Company Overview - Innovent Biologics is a China-based biopharmaceutical company with a global perspective, focusing on the comprehensive development and commercialization of innovative drugs [10]. Recent Developments - The deal with Eli Lilly involves early development led by Innovent from proof of concept to Phase II, after which Eli Lilly will handle late-stage development and commercialization outside China [5]. - The assets involved in this transaction are undisclosed clinical projects, and the number of projects is fewer than the 11 preclinical assets involved in a previous deal between Hengrui Medicine and GSK [5]. Financial Performance - Innovent's product sales for Q4 2025 reached 3.3 billion yuan, representing a year-on-year growth of over 60%, exceeding market consensus expectations [6]. Catalysts - Key catalysts for 2026 include updates on proof of concept data for IBI363 in frontline non-small cell lung cancer and the initiation of multiple global Phase III projects led by Takeda [7].